The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | TAK-079: an anti-CD38 antibody for R/R MM
Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, discusses the preliminary results from a Phase Ib study (NCT03439280) of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma (R/R MM). Emerging data show subcutaneous injection of mezagitamab induced objective response rate in 43% of the heavily pretreated patients with no infusion reaction and no drug-related lymphopenia or thrombocytopenia. As this is an ongoing trial, a cohort of patients who are refractory to previous anti-CD38 antibodies will enroll the study to further analyze the activity of mezagitamab. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
